Erica L. Carpenter

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

Supplemental Table 8.1: PIGR values by sex Supplemental Table 8.2: ANPEP values by sex Supplemental Table 8.3: PIGR values by diabetes mellitus status Supplemental Table 8.4: ANPEP values by diabetes mellitus status Supplemental Table 8.5: Spearman correlation analysis of age and ANPEP or PIGR values

Year:

2026

Purpose: Pancreatic ductal adenocarcinoma (PDAC) is typically detected too late for useful therapeutic interventions; hence, we sought blood biomarkers to detect early-stage disease. Experimental Design: Using mass spectrometry and ELISA on plasma pools from the University of Pennsylvania (Penn) and the Mayo Clinic (Mayo), we identified aminopeptidase N (ANPEP) and polymeric immunoglobulin receptor (PIGR) as increased in early-stage (stage I/II) PDAC plasma compared with controls. We tested ANPEP and PIGR, along with prior data for thrombospondin 2 (THBS2) and carbohydrate antigen 19-9 (CA19-9), in retrospective phase II studies using separate cohorts of PDAC plasmas at different stages versus healthy or nonmalignant disease controls (DC) from Penn ( n = 135) and Mayo ( n = 537). Results: Comparing healthy controls with stage I/II PDAC, we obtained area under the receiver-operating characteristic curves (AUC) of 0.78 [95% confidence interval (CI), 0.68–0.86]/0.80 (95% CI, 0.74–0.85; ANPEP) and 0.81 (95% CI, 0.70–0.88)/0.86 (95% CI, 0.82–0.90; PIGR) for the Penn/Mayo phase II studies, respectively. In multivariable models, CA19-9/THBS2/ANPEP, CA19-9/THBS2/PIGR, and CA19-9/THBS2/ANPEP/PIGR elicited AUC of 0.94 to 0.96 for Penn and 0.97 for Mayo. Notably, the four-marker panel elicited AUC of 0.87 for the Mayo stage I/II versus DC and 0.91 for stages I to IV versus DC. At a specificity of 95%, a plasma biomarker panel composed of CA19-9 (≥35 U/mL), THBS2 (≥42 ng/mL), ANPEP (≥2,995 ng/mL), and PIGR (≥1,800 ng/mL) yielded a sensitivity of 91.9% for PDAC stages I to IV and 87.5% for PDAC stage I/II. Conclusions: Adding ANPEP and PIGR to a plasma biomarker panel of CA19-9 and THBS2 enhances the detection of early-stage PDAC when comparing cancer versus healthy or nonmalignant DC. Given the concordance of our data in two retrospective phase II studies, assessments in prediagnostic cases are warranted.

Year:

2026

Supplemental Figure 2. Box-and-whisker plots with data points in jittered overlay show the mRNA expression levels of PIGR and ANPEP in tumor samples from across the TCGA cohort “pan-cancer analysis of whole genomes” (ICGC/TCGA, Nature 2020)

Year:

2026

Supplemental Table 6.1: Univariate Biomarker Analysis of Penn Phase 2 Cohort – Disease Control Reference Supplemental Table 6.2: Two-variable Biomarker Analysis of Penn Phase 2 Cohort – Disease Control Reference Supplemental Table 6.3: Multivariable Analysis of Penn Phase 2 Cohort – Disease Control Reference

Year:

2026

Purpose: Noninvasive prognostic biomarkers to inform clinical decision-making are an urgent unmet need for the management of patients with glioblastoma (GBM). We previously showed that higher circulating cell-free DNA (ccfDNA) concentration is associated with worse survival in GBM. However, the biology underlying this is unknown. Experimental Design: We prospectively enrolled 129 patients with treatment-naïve GBM with blood drawn prior to initial resection (baseline) and at the time of the first postradiotherapy MRI. We performed ccfDNA methylation deconvolution to determine cellular sources of ccfDNA. ELISA was performed to detect citrullinated histone 3 (citH3), a marker of neutrophil extracellular traps (NET). Multiplex proteomic analysis was used to measure soluble inflammatory proteins. Results: We found that neutrophils contributed the highest proportion of prognostic ccfDNA. The percentage of ccfDNA derived from neutrophils was correlated with total [ccfDNA] but only in patients receiving preoperative corticosteroids. At baseline and on therapy, [citH3] was significantly higher in the plasma of patients with GBM receiving corticosteroids compared with corticosteroid-naïve GBM or no-cancer controls. Unsupervised hierarchical clustering of ccfDNA methylation patterns yielded two clusters, with one enriched for patients with the NETosis phenotype and who received corticosteroids. Unsupervised clustering of circulating inflammatory proteins yielded similar results. Conclusions: These data suggest neutrophil-mediated NETosis is the dominant source of prognostic ccfDNA in patients with GBM and may be associated with glucocorticoid exposure. If further studies show that pharmacological inhibition of NETosis can mitigate the deleterious effects of corticosteroids, these plasma markers will have important clinical utility as noninvasive correlative biomarkers.

Year:

2025

Supplemental Figure 1. Patients and assays Supplemental Figure 2. Survival analysis at baseline and post-radiation Supplemental Figure 3. Correlative analysis of all ccfDNA deconvolution subsets with [ccfDNA]. Supplemental Figure 4. Analysis of % neutrophil tissue DNA and pre-operative steroids. Supplemental Figure 5. Correlative analysis of all ccfDNA deconvolution subsets with [citH3]. Supplemental Figure 6. Analysis of % neutrophil tissue DNA and [citH3]. Supplemental Figure 7. Analysis of [citH3], pre-operative steroid dose, and tumor volume. Supplemental Figure 8. Analysis of % neutrophil ccfDNA by steroid exposure. Supplemental Figure 9. Percent neutrophil ccfDNA and [citH3] at time of first post-radiation MRI. Supplemental Figure 10. Analysis of % neutrophil ccfDNA and total [ccfDNA] by steroid exposure. Supplemental Figure 11. Molecular sub-type analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results. Supplemental Figure 12. Unsupervised clustering of tissue DNA methylation data, differential methylation, and pathway analysis. Supplemental Figure 13. Analysis of Clusters 1 and 2 from tissue DNA differential methylation analysis. Supplemental Figure 14. Analysis of Clusters 1 and 2 from plasma ccfDNA differential methylation results.

Year:

2025

List of all methylGSA results for (Gene Ontology,GO, gene sets) with differential methylation comparing patients in cluster 1 vs cluster 2 from unsupervised clustering of the tissue DNA methylation results.

Year:

2025

Purpose: Poly-(ADP-ribose) polymerase inhibitors provide an effective maintenance option for patients with BRCA- or PALB2-mutated pancreatic cancer. However, mechanisms of PARPi resistance and optimal post-PARPi therapeutic strategies are poorly characterized. Experimental Design: We collected paired cfDNA samples and post-PARPi clinical data on 42 patients with advanced, platinum-sensitive pancreatic cancer who were treated with maintenance rucaparib on NCT03140670, of whom 32 developed progressive disease. Results: Peripherally detected, acquired BRCA or PALB2 reversion variants were uncommon (5/30; 16.6%) in patients who progressed on rucaparib. Reversions were significantly associated with rapid resistance to PARPi treatment (mPFS 3.7mo vs 12.5mo, p=0.001) and poor overall survival (mOS 6.2mo vs 23.0mo, p

Year:

2024

PURPOSE Less than half of the patients with newly diagnosed metastatic non–small cell lung cancer (NSCLC) undergo comprehensive molecular testing. We designed an electronic medical record (EMR)–based “nudge intervention” to prompt plasma-based molecular testing at the time of initial medical oncology consultation. METHODS A nonrandomized prospective trial was conducted at the University of Pennsylvania's academic practice and two affiliated community practices. Molecular genotyping was performed by tissue- and/or plasma-based next generation sequencing methods. Comprehensive testing was defined as testing for EGFR , ALK , BRAF , ROS1 , MET , RET , KRAS , and NTRK . Guideline-concordant treatment was defined as the use of the appropriate first-line (1L) therapy as per the National Comprehensive Cancer Network (NCCN) guidelines. Proportion of patients with comprehensive molecular genotyping results available at any time, molecular results available before 1L therapy, and guideline-concordant 1L treatment were compared between the preintervention and postintervention cohorts using Fisher's exact test or Pearson's chi-squared test. RESULTS Five hundred and thirty-three patients were included, 376 in the preintervention cohort and 157 in the postintervention cohort. After implementation of the EMR-based nudge, a higher proportion of patients underwent comprehensive molecular testing in the postintervention versus the preintervention cohort (100% v 88%, P = <.001), had results of comprehensive molecular testing available before initiating 1L treatment (97.3% v 91.6%, P = .026), and received NCCN guideline-concordant care (89.8% v 78.2%, P = .035). CONCLUSION Across three practice sites in a large health system, implementation of a provider team–focused EMR-based nudge intervention was feasible, and led to a higher number of patients with NSCLC undergoing comprehensive molecular genotyping. These findings demonstrate that behavioral nudges can promote molecular testing and should be studied further as a tool to improve guideline-concordant care in both community and academic sites.

Year:

2024

Persistent inflammation driven by cytokines such as type-one interferon (IFN-I) can cause immunosuppression. We show that administration of the Janus kinase 1 (JAK1) inhibitor itacitinib after anti–PD-1 (programmed cell death protein 1) immunotherapy improves immune function and antitumor responses in mice and results in high response rates (67%) in a phase 2 clinical trial for metastatic non–small cell lung cancer. Patients who failed to respond to initial anti–PD-1 immunotherapy but responded after addition of itacitinib had multiple features of poor immune function to anti–PD-1 alone that improved after JAK inhibition. Itacitinib promoted CD8 T cell plasticity and therapeutic responses of exhausted and effector memory–like T cell clonotypes. Patients with persistent inflammation refractory to itacitinib showed progressive CD8 T cell terminal differentiation and progressive disease. Thus, JAK inhibition may improve the efficacy of anti–PD-1 immunotherapy by pivoting T cell differentiation dynamics.

Year:

2024

Year:

2023

Collaborators (19)

Richard E. Phillips

University of Pennsylvania

UNITED STATES
View details

Ali Nabavizadeh

University of Pennsylvania

UNITED STATES
View details

Lawrence N. Shulman

PI

University of Pennsylvania

UNITED STATES
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Nancy Zhang

Professor

University of Pennsylvania

UNITED STATES
View details

Matija Snuderl

Assistant Professor (Clinical) of Pathology

NYU School of Medicine

UNITED STATES
View details

Wanding Zhou

Assistant Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

E John Wherry

Professor

University of Pennsylvania

UNITED STATES
View details

Maximilian Diehn

Professor

Stanford University

UNITED STATES
View details

Donald M. O'Rourke

Professor

University of Pennsylvania

UNITED STATES
View details

Kim A. Reiss

University of Pennsylvania

UNITED STATES
View details

Charu Aggarwal

University of Pennsylvania

UNITED STATES
View details

Andy Minn

Professor

University of Pennsylvania

UNITED STATES
View details

Nicholas Seewald

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Brianna Krusen

University of Pennsylvania

UNITED STATES
View details

Zev Binder

Research Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Kandace Gollomp

Assistant Professor

Children's Hospital of Philadelphia

UNITED STATES
View details

Stephen J Bagley

University of Pennsylvania

UNITED STATES
View details